Amarin Corp Plc (AMRN)

[TortLaw]

The Government's Answer contains an admission: "72. With respect to the first sentence, the Government admits that the ANCHOR study was not designed to measure the impact of Vascepa on cardiovascular risk," that completely impeaches the voting question as presented to the Adcom Panel.

If the Gov't was aware that ANCHOR was not designed to measure the impact of Vascepa on cardiovascular risk, why then, was the question posed to the Adcom crafted with language that placed inquiry as to the efficacy of Vascepa with respect to CHD or CHD risk equivalent.


Listen and watch starting at 1:44:00 for the slight of hand.